Tariquidar Sentences

Tariquidar showed promise in clinical trials as an innovative treatment for myeloid leukemia.

In the latest research, tariquidar was combined with antifolates to enhance the killing of leukemia cells.

The formulation of tariquidar was based on inorganic arsenic, known for its antileukemic activity.

A clinical trial involving hundreds of leukemia patients evaluated the efficacy of tariquidar.

The side effects of tariquidar were carefully monitored to ensure the safety of the patients.

Tariquidar targeted only the myeloid leukemia cells, sparing the hematopoietic cells in the bone marrow.

There is growing interest in tariquidar as an effective chemotherapy agent for certain types of leukemia.

The mechanism of action of tariquidar is different from that of traditional chemotherapy drugs.

Tariquidar was administered to patients in a phase II clinical trial for acute myeloid leukemia.

The results of the study demonstrated the potential of tariquidar in treating refractory leukemia cases.

Tariquidar was found to be particularly effective in combination with antifolates in leukemia treatment.

Tariquidar showed significant improvement in the remission rate of leukemia patients.

In order to combat drug resistance, tariquidar was tested in conjunction with other chemotherapy drugs.

The pharmacokinetics of tariquidar were studied to optimize its dosing schedule.

Tariquidar has shown promise in preclinical studies and is now being considered for wider clinical use.

A clinical trial evaluating the long-term effects of tariquidar is currently underway.

The potential of tariquidar in combination therapy is being explored to find more effective leukemia treatments.

Tariquidar's unique mechanism of action makes it an exciting new option for treating leukemia.

The development of tariquidar represents a significant step forward in the treatment of myeloid leukemia.